XML 56 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Long-term Debt - Additional Information (Detail)
6 Months Ended
Mar. 31, 2020
Jan. 08, 2020
USD ($)
Tranche
Dec. 28, 2017
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]          
Line of credit facility, advance amount       $ 20,000,000.0  
Line of credit facility, interest rate     8.05%    
Borrowings outstanding       24,252,000  
Discount on borrowings       $ 748,000  
Hercules Capital Inc [Member]          
Debt Instrument [Line Items]          
Purchase of common stock   $ 1,000,000.0      
Tranche One [Member]          
Debt Instrument [Line Items]          
Line of credit facility, interest rate   8.50%      
Term Loan [Member]          
Debt Instrument [Line Items]          
Line of credit facility, maximum borrowing capacity     $ 50,000,000.0    
Line of credit facility, interest rate       8.05%  
Line of credit facility, interest rate description       As of June 30, 2020, the Company had borrowed $20.0 million under the Credit Facility, with an interest rate of 8.05% per annum and the remaining available amount had expired.  Advances under the Credit Facility bear an interest rate equal to the greater of either (i) 8.05% plus the prime rate as reported from time to time in The Wall Street Journal (the Prime Rate) minus 4.75%, and (ii) 8.05%. The Company will make interest-only payments through July 1, 2021, and will then repay the principal balance and interest on the advances in equal monthly installments and continuing through December 1, 2022. The Company will pay an end of term charge of $1.3 million.  
Line of credit facility, maturity date       Dec. 01, 2022  
Payment of end term charge       $ 1,300,000  
Loan commitment charge, percentage   1.00%      
Borrowings outstanding       24,252,000 $ 19,786,000
Discount on borrowings       $ 748,000 $ 214,000
Term Loan [Member] | Minimum [Member]          
Debt Instrument [Line Items]          
Loan commitment charge   $ 162,500      
Aggregate proceeds to be received from equity offering   30,000,000.0      
Term Loan [Member] | Maximum [Member] | Hercules Capital Inc [Member]          
Debt Instrument [Line Items]          
Amount of participation in equity financing   3,000,000.0      
Term Loan [Member] | Wall Street Journal Prime [Member]          
Debt Instrument [Line Items]          
Line of credit facility, interest rate       4.75%  
Term Loan Restated [Member]          
Debt Instrument [Line Items]          
Line of credit facility, maximum borrowing capacity   $ 100,000,000.0      
Line of credit facility, interest rate description       In addition, the Company may prepay advances under the Amended Loan Agreement, in whole or in part, at any time, subject to a prepayment charge that ranges from 1.0% to 2.0%, depending on the timing of the prepayment. The Amended Loan Agreement is secured by substantially all of the Company’s assets, excluding intellectual property. The Amended Loan Agreement also includes customary loan covenants, with which the Company was in compliance for all periods presented.  
Number of tranches | Tranche   3      
Term Loan Restated [Member] | Minimum [Member]          
Debt Instrument [Line Items]          
Loan commitment charge   $ 520,000      
Term Loan Restated [Member] | Tranche One [Member]          
Debt Instrument [Line Items]          
Line of credit facility, advance amount       $ 5,000,000.0  
Line of credit facility, interest rate 8.50%        
Line of credit facility, interest rate description       Under the Restated Credit Facility, the Company had borrowed $5.0 million from the first tranche with an interest rate of 8.50% per annum as of June 30, 2020.  Advances under the Restated Credit Facility bear an initial interest rate equals to the greater of either (i) 8.50% plus the Prime Rate minus 5.25%, and (ii) 8.50%, which may be reduced upon the Company achieving certain cumulative net avacopan revenue levels. For advances under the Restated Credit Facility, the Company will make interest only payments through September 1, 2022 and will then repay the principal balance and interest on the advances in equal monthly installments through February 1, 2024. Upon satisfaction of certain conditions, the interest-only payment period and the principal balance repayment period may be extended.  In addition, the Company will pay an end of term charge of 7.15% of the aggregate amount of the advances under the Restated Credit Facility.  
Line of credit facility, maturity date       Feb. 01, 2024  
End of term charge advances, percentage       7.15%  
Term Loan Restated [Member] | Wall Street Journal Prime [Member] | Tranche One [Member]          
Debt Instrument [Line Items]          
Line of credit facility, interest rate       5.25%  
Through December 15, 2020 [Member] | Tranche One [Member]          
Debt Instrument [Line Items]          
Line of credit facility, maximum borrowing capacity   40,000,000.0      
Through December 15, 2020 [Member] | Tranche One [Member] | Avacopan New Drug Application          
Debt Instrument [Line Items]          
Line of credit facility, capacity available for specific purpose other than for trade purchases   20,000,000.0      
Through December 15, 2021 [Member] | Tranche Two [Member] | Avacopan New Drug Application          
Debt Instrument [Line Items]          
Restated credit facility, maximum borrowing capacity   30,000,000.0      
Through December 15, 2022 [Member] | Tranche Three [Member]          
Debt Instrument [Line Items]          
Line of credit facility, maximum borrowing capacity   $ 30,000,000.0